Skip to main content
. 2018 Oct 12;25(5):831–842. doi: 10.1093/ibd/izy313

Table 5.

Metabolic Conditions Associated With New Agents and Suggested Management

Therapeutic Target Liver Enzyme Abnormality Lipids/Creatine Kinase
TNF Continue: if <2x ULN
Stop: >2x ULN or (+) Hepatitis B or autoimmune hepatitis
Continue
Integrin Continue, but monitor Continue
IL 12/23 Continue Continue
JAK Continue Continue, but monitor

IL: interleukin; JAK: Janus kinase; ULN: upper limit of normal